Jared Keller
@Kynam Capital Management, Lp
Latest period2024 - Q3ReportedManaged Assets$1.304BTotal holdings25
Assets growth rate0.63%Assets growth rate (2-Q avg)18.16%Continuous growth in asset value4 quarters
Portfolio positions
This chart displays the top 10 holdings in Kynam Capital Management, Lp's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 25 positions.
Assets under management
The assets under management (AUM) of Kynam Capital Management, Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 4 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 1.304B in assets, with a quarterly growth rate of 0.63% and a 2-quarter average growth rate of 18.16%. The portfolio is managed by Jared Keller, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
NTRANatera Inc
| 19.88% | $259.292M 2.042M shares@ $126.95 avg price | Increased 1.4% |
PCVXVaxcyte Inc
| 9.11% | $118.759M 1.039M shares@ $114.28 avg price | Increased 37.98% |
CLDXCelldex Therapeutics Inc New
| 9.02% | $117.558M 3.459M shares@ $34.0 avg price | Increased 2.06% |
SNDXSyndax Pharmaceuticals Inc
| 8.63% | $112.476M 5.843M shares@ $19.25 avg price | Increased 2.12% |
COGTCogent Biosciences Inc
| 7.65% | $99.789M 9.24M shares@ $10.81 avg price | Decreased -0.22% |
DVAXDynavax Technologies Corp
| 7.12% | $92.826M 8.333M shares@ $11.14 avg price | Increased 17.66% |
VERAVera Therapeutics Inc
| 5.35% | $69.683M 1.577M shares@ $44.21 avg price | Increased 2.13% |
BCRXBiocryst Pharmaceuticals Inc
| 5.3% | $69.049M 9.085M shares@ $7.61 avg price | Increased 2.94% |
CGONCg Oncology Inc
| 5.13% | $66.812M 1.771M shares@ $37.74 avg price | Increased 3184.69% |
VRDNViridian Therapeutics Inc
| 4.38% | $57.132M 2.511M shares@ $22.75 avg price | Increased 43.51% |